AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7052184 — intervention group
Group type: COMPARATOR
Intervention: Activity group
Number of subjects: 38
Study 7052184 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT treatment
Number of subjects: 38
Study 7052184 — intervention group
Group type: COMPARATOR
Intervention: Discussion group and Activity group
Number of subjects: 38
Study 30514777 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT methylation status (unmethylated, gray zone, methylated)
Number of subjects: 4041
Study 30514777 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT assay
Number of subjects: 4041
Study 29110641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification and peer support home blood pressure monitoring
Number of subjects: 0
Study 26205609 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing an up-to-date medical information sheet about BRCA1/2 genetic topics and a photograph with the names of the researchers
Number of subjects: 235
Study 26205609 — intervention group
Group type: COMPARATOR
Intervention: Providing a leaflet about aggregate psychosocial research results
Number of subjects: 235
Study 23917472 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened stride length
Number of subjects: 19
Study 23917472 — intervention group
Group type: COMPARATOR
Intervention: Greater stride length
Number of subjects: 19
Study 22001911 — intervention group
Group type: COMPARATOR
Intervention: Normoxic (NM: 21% FIO2)
Number of subjects: 20
Study 22001911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxic (HY: 13% FIO2)
Number of subjects: 20
Study 19161480 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL)
Number of subjects: 89
Study 19161480 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty staff-led training
Number of subjects: 89
Study 19161480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 89
Study 17541944 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS160 in incomplete Freund adjuvant (Montanide ISA‐51)
Number of subjects: 28
Study 17541944 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS160 in Montanide ISA‐51 with 75 microg of granulocyte‐macrophage‐stimulating factor (GM‐CSF)
Number of subjects: 28
Study 17541944 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS160 in Montanide ISA‐51 with 100 microg of GM‐CSF
Number of subjects: 28
Study 15808922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (iv) ghrelin administration (1.0 microg/kg) in bulimia nervosa (BW)
Number of subjects: 16
Study 15808922 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (iv) ghrelin administration (1.0 microg/kg) in healthy women (HW)
Number of subjects: 16
Study 11920413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 84
Study 11920413 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 10 mg
Number of subjects: 84
Study 10354910 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) at 5.0 hPa
Number of subjects: 0
Study 10354910 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP)
Number of subjects: 0
Study 10354910 — intervention group
Group type: COMPARATOR
Intervention: Non-expiratory positive pressure (NPEP)
Number of subjects: 0
Study 7743622 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity, home-based exercise (3 sessions/week, 40 minutes at 73%-88% peak heart rate)
Number of subjects: 269
Study 7743622 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity, home-based exercise (5 sessions/week, 30 minutes at 60%-73% peak heart rate)
Number of subjects: 269
Study 7743622 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity, group-based exercise (3 sessions/week, 40 minutes at 73%-88% peak heart rate)
Number of subjects: 269
Study 7743622 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise conditions
Number of subjects: 269
Study 2254718 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal milk (1180 mg Ca2+, 1650 mg K+, 110 mg Mg2+ d‐1)
Number of subjects: 0
Study 2254718 — intervention group
Group type: COMPARATOR
Intervention: Mineral-poor milk (95 mg Ca2+, 580 mg K+, 10 mg Mg2+ d‐1)
Number of subjects: 0
Study 7410779 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 36
Study 7410779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7410779 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 31792321 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Variational Autoencoder (VAE)
Number of subjects: 3832
Study 31792321 — intervention group
Group type: COMPARATOR
Intervention: Point-wise (PW) regression
Number of subjects: 3832
Study 27750388 — intervention group
Group type: EXPERIMENTAL
Intervention: T4‐like coliphage cocktail
Number of subjects: 109
Study 27750388 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial phage preparation (Coliproteus from Microgen/Russia)
Number of subjects: 109
Study 27750388 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration therapy
Number of subjects: 109
Study 27750388 — intervention group
Group type: COMPARATOR
Intervention: Coliphage preparations or placebo
Number of subjects: 109
Study 25678311 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention consisting of physical fitness training combined with counselling sessions focusing on physical behaviour and sports participation.
Number of subjects: 57
Study 25678311 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 57
Study 22840185 — intervention group
Group type: EXPERIMENTAL
Intervention: Training care staff to observe and identify signs of awareness in residents (n = 32) over an eight-week period
Number of subjects: 65
Study 22840185 — intervention group
Group type: COMPARATOR
Intervention: No training for care staff (n = 33)
Number of subjects: 65
Study 21786113 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin-based cream (Leviaderm(®))
Number of subjects: 101
Study 21786113 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 101
Study 19138415 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF after 6 cycles of unsuccessful IUI
Number of subjects: 103
Study 19138415 — intervention group
Group type: COMPARATOR
Intervention: Immediate IVF without preceding IUI
Number of subjects: 103
Study 17588273 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol
Number of subjects: 92
Study 17588273 — intervention group
Group type: COMPARATOR
Intervention: Manual-controlled infusion of propofol
Number of subjects: 92
Study 15450782 — intervention group
Group type: COMPARATOR
Intervention: Bipolar disorder patients
Number of subjects: 239
Study 11229823 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III supplementation (50 U/kg) by intravenous infusion prior to incision
Number of subjects: 20
Study 11229823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9893913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (0.15 mg/kg)
Number of subjects: 30
Study 9893913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 30
Study 7983646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 71
Study 7983646 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 71
Study 2691569 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐alpha 2c, 10 MU/m2 body surface, twice weekly, intramuscularly for 6 months
Number of subjects: 20
Study 2691569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 1090684 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% micronized griseofulvin applied 3 times daily for 3 weeks
Number of subjects: 52
Study 1090684 — intervention group
Group type: COMPARATOR
Intervention: 1% tolnaftate cream
Number of subjects: 52
Study 1090684 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 52
Study 30593974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment (CAST)
Number of subjects: 91
Study 30593974 — intervention group
Group type: COMPARATOR
Intervention: Physical health education training (control)
Number of subjects: 91
Study 28549145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lots of rVSVΔG‐ZEBOV‐GP (2 × 10^7 pfu, n = 797)
Number of subjects: 1197
Study 28549145 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rVSVΔG‐ZEBOV‐GP (1 × 10^8 pfu, n = 264)
Number of subjects: 1197
Study 28549145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 133)
Number of subjects: 1197
Study 25983669 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency cherry juice (CJ)
Number of subjects: 20
Study 25983669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 24192410 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-stimulable phosphor (PSP) plates
Number of subjects: 59
Study 24192410 — intervention group
Group type: COMPARATOR
Intervention: Film
Number of subjects: 59
Study 21550589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) consisting of 6 sessions combining behavioural sleep medicine techniques and anxiety treatment techniques
Number of subjects: 42
Study 21550589 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 42
Study 19687350 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril (5.0/20.0 mg, 5.0/40.0 mg, 10.0/40.0 mg)
Number of subjects: 125
Study 19687350 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide/benazepril (12.5/20.0 mg, 12.5/40.0 mg, 25.0/40.0 mg)
Number of subjects: 125
Study 19687350 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Amlodipine/benazepril vs Hydrochlorothiazide/benazepril
Number of subjects: 125
Study 19687350 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril in female patients
Number of subjects: 125
Study 16971360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene plus hydroquinone (4% cream)
Number of subjects: 131
Study 16971360 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene alone (0.1% cream)
Number of subjects: 131
Study 14755009 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation/maintenance therapy
Number of subjects: 0
Study 14755009 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11069800 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (256 microg; Rhinocort Aqua)
Number of subjects: 9
Study 11069800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9263752 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 1.5 micrograms per day for 7 days
Number of subjects: 18
Study 9263752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9263752 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 18
Study 8325766 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of the first seizure
Number of subjects: 498
Study 8325766 — intervention group
Group type: COMPARATOR
Intervention: Treatment of recurrences
Number of subjects: 498
Study 3828184 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position for subarachnoid analgesia
Number of subjects: 35
Study 3828184 — intervention group
Group type: COMPARATOR
Intervention: Left lateral position for subarachnoid analgesia
Number of subjects: 35
Study 28871492 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics + Probiotics (Lactobacillus rhamnosus GG)
Number of subjects: 90
Study 28871492 — intervention group
Group type: COMPARATOR
Intervention: Only Antibiotics
Number of subjects: 90
Study 28871492 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics + Placebo (glucose solution at 5%)
Number of subjects: 90
Study 28361113 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bodyweight-based tacrolimus starting dose
Number of subjects: 203
Study 28361113 — intervention group
Group type: COMPARATOR
Intervention: CYP3A5 genotype-based tacrolimus starting dose
Number of subjects: 203
Study 26653236 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization of bronchial artery (BAE)
Number of subjects: 115
Study 26653236 — intervention group
Group type: COMPARATOR
Intervention: Internal medicine (control)
Number of subjects: 115
Study 23318478 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month interval surveillance (group A)
Number of subjects: 744
Study 23318478 — intervention group
Group type: COMPARATOR
Intervention: 12-month interval surveillance (group B)
Number of subjects: 744
Study 20925972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency right rTMS to the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 219
Study 20925972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential low-frequency right-sided followed by high-frequency left-sided rTMS
Number of subjects: 219
Study 20925972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential low-frequency rTMS to both hemispheres
Number of subjects: 219
Study 20925972 — intervention group
Group type: COMPARATOR
Intervention: Unilateral right-sided rTMS
Number of subjects: 219
Study 20925972 — intervention group
Group type: COMPARATOR
Intervention: Bilateral rTMS (both forms)
Number of subjects: 219
Study 18167382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid 5 mg
Number of subjects: 7714
Study 18167382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7714
Study 16598468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.05 mg/ml) applied topically to the filtering bleb for 5 min on the 3 days after surgery
Number of subjects: 52
Study 16598468 — intervention group
Group type: COMPARATOR
Intervention: No mitomycin C applied (control group)
Number of subjects: 52
Study 13678971 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 616
Study 13678971 — intervention group
Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 616
Study 13678971 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 616
Study 10883563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (men's group)
Number of subjects: 861
Study 10883563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (conjoint group)
Number of subjects: 861
Study 10883563 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 861
Study 9232359 — intervention group
Group type: EXPERIMENTAL
Intervention: BRS-sequence method
Number of subjects: 14
Study 9232359 — intervention group
Group type: COMPARATOR
Intervention: Valsalva manoeuvre
Number of subjects: 14
Study 9232359 — intervention group
Group type: EXPERIMENTAL
Intervention: BRS-sequence method and Valsalva manoeuvre
Number of subjects: 14
Study 1317524 — intervention group
Group type: EXPERIMENTAL
Intervention: PS600 haemodialysis
Number of subjects: 15
Study 1317524 — intervention group
Group type: COMPARATOR
Intervention: PS400 dialysis
Number of subjects: 15
Study 1317524 — intervention group
Group type: COMPARATOR
Intervention: PS600 haemodiafiltration
Number of subjects: 15
Study 2866932 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 26
Study 2866932 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg) with Hydrochlorothiazide (50 mg)
Number of subjects: 26
Study 2866932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Atenolol + Amiloride + Hydrochlorothiazide)
Number of subjects: 26
Study 2866932 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker
Number of subjects: 26
Study 2866932 — intervention group
Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 26
Study 2866932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 26
Study 2866932 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic treatment alone or in combination
Number of subjects: 26
Study 31075767 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional vacuum-assisted closure (VAC)
Number of subjects: 64
Study 31075767 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressings (control)
Number of subjects: 64
Study 30347072 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 2% mouthwash
Number of subjects: 8665
Study 30347072 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD (mouthpaste with colistin, tobramycin, and nystatin)
Number of subjects: 8665
Study 30347072 — intervention group
Group type: EXPERIMENTAL
Intervention: SDD (mouthpaste and gastrointestinal suspension with the same antibiotics)
Number of subjects: 8665
Study 30347072 — intervention group
Group type: COMPARATOR
Intervention: Standard care (baseline period)
Number of subjects: 8665
Study 26864367 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powders (MNPs) marketed in intervention villages
Number of subjects: 1062
Study 26864367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MNPs marketed)
Number of subjects: 1062
Study 25171966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cre8 DES
Number of subjects: 38
Study 25171966 — intervention group
Group type: COMPARATOR
Intervention: Vision/Multilink8 BMS
Number of subjects: 38
Study 22539545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol treatment
Number of subjects: 230
Study 22539545 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and 7 months follow-up
Number of subjects: 230
Study 22539545 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B/A-I levels
Number of subjects: 230
Study 22539545 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B/A-I at 7 months
Number of subjects: 230
Study 22539545 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant lipoprotein cholesterol levels
Number of subjects: 230
Study 22539545 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol elevation
Number of subjects: 230
Study 20146685 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary interventions (PCI) with drug eluting stents (DES)
Number of subjects: 0
Study 20146685 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 0
Study 17617802 — intervention group
Group type: EXPERIMENTAL
Intervention: Light bandage (25 patients)
Number of subjects: 50
Study 17617802 — intervention group
Group type: COMPARATOR
Intervention: Bulky dressing with a volar splint (25 patients)
Number of subjects: 50
Study 15995768 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral cervical traction headgear
Number of subjects: 26
Study 17118822 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 0
Study 17118822 — intervention group
Group type: COMPARATOR
Intervention: Ischemic-reperfusion (IR) group
Number of subjects: 0
Study 10365577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultamicillin (4 days orally)
Number of subjects: 85
Study 10365577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 days orally)
Number of subjects: 85
Study 8681927 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H (4-5 sets of 15-20 RM with sufficient rest between sets)
Number of subjects: 11
Study 8681927 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (8-9 sets of 4-6 RM with 90 s of rest between sets)
Number of subjects: 11
Study 1994402 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose urokinase (250,000 U/h for 4 hours and then 125,000 U/h)
Number of subjects: 63
Study 1994402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose urokinase (50,000 U/h)
Number of subjects: 63
Study 1994402 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose urokinase
Number of subjects: 63
Study 1994402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose urokinase
Number of subjects: 63
Study 6614537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV) with respiratory frequency maintained at 100/min and I/E ratios of 0.25, 0.43, and 0.67 (Group A)
Number of subjects: 24
Study 6614537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV) with I/E ratio maintained at 0.43 and varying respiratory frequencies (Group B)
Number of subjects: 24
Study 31498250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor system for early illness recognition
Number of subjects: 55
Study 28849895 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup-specific pain rehabilitation program based on the Multidimensional Pain Inventory (MPI) Classification System
Number of subjects: 139
Study 28849895 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 139
Study 25828951 — intervention group
Group type: EXPERIMENTAL
Intervention: Three narrow diameter implants placed using osteotomes with a one-stage procedure and 12-week loading.
Number of subjects: 40
Study 24503174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 58
Study 22906283 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% chloroprocaine with adrenaline (group CA)
Number of subjects: 60
Study 22906283 — intervention group
Group type: COMPARATOR
Intervention: 3% chloroprocaine (group C)
Number of subjects: 60
Study 22906283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with adrenaline (group LA)
Number of subjects: 60
Study 20106646 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA (3.4 g/d)
Number of subjects: 0
Study 20106646 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (650 mg)
Number of subjects: 0
Study 20106646 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 17295758 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetic agents (metoclopramide, domperidone, trimebutine, cisapride, itopride, mosapride)
Number of subjects: 1844
Study 17295758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1844
Study 16086935 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU) and Vitamin C (1000 mg) daily
Number of subjects: 100
Study 16086935 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg) only
Number of subjects: 100
Study 16086935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 100